Emily Chang meets Nobel Prize-winning scientist and University of California, Berkeley, Professor Jennifer Doudna to discuss the origins of CRISPR, other breakthroughs in gene editing and what Silicon...

The technology could tackle diseases such as atherosclerosis and hepatitis B

Nov 17, 2025

Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them. However, many approaches still strugg...

Scribe Therapeutics Inc. is aiming to advance STX-1150, its lead product candidate for the treatment of hypercholesterolemia, into the clinic around the middle of this year. Hypercholesterolemia is a ...

A second milestone for Scribe and Lilly highlights growing confidence in CRISPR as a tool for longer, healthier lives.

Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mains...